Study S002574

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMF-650 in Otherwise Healthy Overweight or Obese Participants.

ClinicalTrials.gov record

Registration

Registration: NCT07223216
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 80
Start: 2025-10-23
Primary completion: 2026-05
Lead sponsor: Biomea Fusion Inc.
Conditions: Obesity
Interventions: DRUG:BMF-650
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Assess safety and tolerability of BMF-650 [6 weeks (Part 1) and 11 weeks (Part 2)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.